Paying the right price for pharmaceuticals: A case study of why the comparator matters

Australian Health Review

Volumn 35, Issue 3, 2011, Pages 267-272

  Spinks, Jean M ^a   Richardson, Jeff R J ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80052188793     PISSN: 01565788     EISSN: 14498944     Source Type: Journal    
DOI: 10.1071/AH10930     Document Type: Article

References (26)

1. International Pharmaceutical Price Differences. Research Report. Canberra: Australian Productivity Commission, AusInfo, 2001. Available at:http://www.pc.gov.au/projects/study/pbsprices/docs/finalreport [verified 28 May 2009].
2. Defina J. Pharmacoeconomics. Today's Life Science 1993; (September): 10-2.
3. Danzon PM, Furukawa FF. International prices and availability of pharmaceuticals in 2005. Health Aff 2008; 27(1): 221-33. doi:10.1377/hlthaff.27. 1.221 (Pubitemid 351198606)
4. Pharmaceutical price controls in OECD countries: Implications for US Consumers, pricing, research and development, and innovation. US Department of Commerce, International Trade Administration, 2004. Available at: http://www.ita.doc.gov/td/chemicals/drugpricingstudy.pdf [verified 15 April 2009].
5. Calfee J, Villarreal M, DuPré E. An exploratory analysis of pharmaceutical price disparities and their implications among six developed nations. American Enterprise Institute (AEI)-Brookings Joint Centre for Regulatory Studies, Working Paper 06-07. Washington, DC: AEI; 2006. Available at http://aei-brookings.org/admin/authorpdfs/redirect-safely. php?fname=./ pdffiles/WP06-07-FINAL.pdf [verified 16 April 2009].
6. Non-patented prescription drug prices reporting. Canadian and Foreign Price Trends, June 2006. Patented Medicine Price Review Board, 2006. Available at: http://www.pmprb-cepmb.gc.ca/english/View.asp?x=805 [verified 16 April 2009].
7. Pharmaceutical Pricing Policies in a Global Market. Organisation for Economic Cooperation and Development (OECD); 2008. Available at http://www.oecd.org/document/36/0, 3343, en-2649-33929-41000996- 1-1-1-37407, 00.html [verified 16 April 2009].
8. Clarke PM, Fitzgerald EM. Expiry of patent protection on statins: effects of pharmaceutical expenditure in Australia. Med J Aust 2010; 192(11): 633-6.
9. MacKay P. Is PHARMAC's sole-supply tendering policy harming the health of New Zealanders? N Z Med J 2005; 118: 1214.
10. Faunce T, Lofgren H, Harvey K, Johnston K. Tendering for low cost generics in Australia. Health Issues. 2006; 87: 26-9. Available at http://papers.ssrn.com/sol3/papers.cfm?abstract-id=1407764 [verified14Feb-ruary 2010].
11. Lofgren H. Generic drugs: International trends and Policy Developments in Australia. Working Paper No. 10. Centre for Strategic Economics Studies, Victoria University of Development; 2002. Available at http://businessandlaw.vu. edu.au/cses/documents/working-papers/pharma/wp 10-2002-pharma.pdf [verified 14 February 2010].
12. Model lists of essential medicines. World Health Organization (WHO); 2009. Available at:L http://www.who.int/medicines/publications/essen tialmedicines/en/[verified 14 March 2010].
13. Annual report for the year ending June 2007. Australian Department of Health and Ageing, Commonwealth Government of Australia, Pharmaceutical Benefits Pricing Authority; 2007. Available at http://www. health.gov.au/internet/main/ publishing.nsf/Content/1E2737E57CEFA BF5CA2575230022E984?OpenDocument [verified 17 April 2009].
14. Scheduleofprices, December 2007. Pharmaceutical Management Agency of New Zealand 2007. Available at http://www.pharmac.govt.nz/2007/12/04/Sched.pdf [verified 17 April 2009].
15. Management Sciences for Health (MSH). International Drug Price Indicator Guide. 2007. Available at http://erc.msh.org/dmpguide/index. cfm?search-cat=yes&display=yes&module=dmp [verified 5 January 2009]
16. Foreign Exchange Rates 2007-2008. Commonwealth of Australia, Australian Taxation Office; 2008. Available at http://www.ato.gov.au/taxprofessionals/ content.asp?doc=/Content/22855.htm&page=4&H4 [verified 5 January 2009].
17. Purchasing Power Parities (PPP) Data, OECD Statistics Directorate. Organisation for Economic Cooperation and Development (OECD); 2008. Available at http://www.oecd.org/document/47/0, 3343, en-2649- 34357-36202863-1-1-1-1, 00.html [verified 17 April 2009].
18. National Medicines Policy. Canberra: Commonwealth Government of Australia, Department of Health and Ageing; 2000. Available at http://www.health.gov.au/internet/main/publishing.nsf/Content/nmp-objecti ves-policy.htm-copy2 [verified 14 February 2010].
19. Clarke PM. Drug deal costing billions. The Weekend Australian, 15-16 May 2010. Available at http://www.theaustralian.com.au/news/health-science/drug- deal-costing-billions-medicines-australia/story-e6frg8y6-1225866384337 [verified].
20. Fact sheet: Pharmaceutical benefits Scheme Reform. Commonwealth Government of Australia, Australian Department of Health and Ageing, Pharmaceutical Benefits Pricing Authority; 2007. Available at: http://www.health.gov.au/internet/main/publishing.nsf/Content/24693658D D49E286CA2572750081DB74/$File/PBS%20Reform%202Feb07.pdf [verified 17 April 2009].
21. Pharmaceutical Benefits Scheme. Memorandum of Understanding-Medicines Australia and the Commonwealth of Australia. Commonwealth Government of Australia, Australian Department of Health and Ageing; 2010. Available at http://www.health.gov.au/internet/main/pub lishing.nsf/Content/further-PBS- reforms-Agreement [verified 3 December 2010].
22. Boer R. Budget Review 2010-11: Health-Pharmaceuticals and Pharmacy. Parliament of Australia. 2010. Available at http://www.aph.gov. au/library/pubs/rp/BudgetReview201011/HealthPharmaceuticals.htm [verified 3 December 2010].
23. Bulfone L. Highprices forgenericsinAustralia-more competition might help. Aust Health Rev 2009; 33: 200-14. doi:10.1071/AH090200
24. McClellan M. Speech before First International Colloquium on generic medicines. US Food and Drug Administration; 2003. Available at http://www.fda.gov/oc/speeches/2003/genericdrug0925.html [verified 17 April 2009].
25. Light DW, Lexchin J. Foreign free riders and the high price of US medicines. BMJ 2005; 331: 958-60. doi:10.1136/bmj.331.7522.958 (Pubitemid 41510858)
26. Sloan C. A history of the Pharmaceutical Benefits Scheme 1947-1992. Canberra: Australian Government Publishing Service; 1995.